AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics Dividend Announcement
• AN2 Therapeutics announced a quarterly dividend of $0.66 per ordinary share which will be made payable on . Ex dividend date: 2018-01-11
• AN2 Therapeutics's trailing twelve-month (TTM) dividend yield is -%
AN2 Therapeutics Dividend History
| Ex-Div date | Dividend amount | Dividend type | Pay date |
|---|---|---|---|
| 2018-01-11 | $0.66 | quarterly | |
| 2017-10-12 | $0.66 | quarterly | |
| 2017-07-12 | $0.66 | quarterly | |
| 2017-04-11 | $0.66 | quarterly | |
| 2017-01-11 | $0.66 | quarterly | |
| 2016-10-12 | $0.66 | quarterly | |
| 2016-07-13 | $0.66 | quarterly | |
| 2016-04-13 | $0.66 | quarterly | |
| 2016-01-13 | $0.66 | quarterly | |
| 2015-10-13 | $0.66 | quarterly | |
| 2015-07-13 | $0.58 | quarterly |
AN2 Therapeutics Dividend per year
AN2 Therapeutics Dividend growth
AN2 Therapeutics Dividend Yield
AN2 Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing AN2 Therapeutics stock? Use our calculator to estimate your expected dividend yield:
AN2 Therapeutics Financial Ratios
P/E ratio-0.50
PEG ratio0.01
P/B ratio0.33
ROE-54.72%
Payout ratio0.00%
Current ratio10.61
Quick ratio10.61
Cash Ratio2.64
AN2 Therapeutics Dividend FAQ
Does AN2 Therapeutics stock pay dividends?
AN2 Therapeutics does not currently pay dividends to its shareholders.
Has AN2 Therapeutics ever paid a dividend?
No, AN2 Therapeutics has no a history of paying dividends to its shareholders. AN2 Therapeutics is not known for its dividend payments.
Why doesn't AN2 Therapeutics pay dividends?
There are several potential reasons why AN2 Therapeutics would choose not to pay dividends to their shareholders:
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.
2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.
3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.
4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.
5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will AN2 Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While AN2 Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is AN2 Therapeutics a dividend aristocrat?
AN2 Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is AN2 Therapeutics a dividend king?
AN2 Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is AN2 Therapeutics a dividend stock?
No, AN2 Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy AN2 Therapeutics stocks?
To buy AN2 Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.
Place an order: Use the brokerage's trading platform to place an order to buy AN2 Therapeutics stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
Place an order: Use the brokerage's trading platform to place an order to buy AN2 Therapeutics stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.